The report provides a detailed analysis essential for establishing a Trimethobenzamide production plant. It encompasses all critical aspects necessary for Trimethobenzamide production, including the cost of Trimethobenzamide production, Trimethobenzamide plant cost, Trimethobenzamide production costs, and the overall Trimethobenzamide production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Trimethobenzamide production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Trimethobenzamide is a non-phenothiazine antiemetic agent that is used for the symptomatic relief of nausea and vomiting. It is used in postoperative states, gastroenteritis (like viral stomach flu), and other gastrointestinal disturbances. It works by centrally antagonising dopamine D2 receptors and modulating activity at the chemoreceptor trigger zone (CTZ) in the medulla oblongata of the brain. It suppresses emetic signals without significant anticholinergic, antihistaminic, or serotonergic activity. It is administered in oral capsule form or as an intramuscular injection, with dosing adjustments for paediatrics based on age and weight. Its common side effects include drowsiness, dizziness, headache, and diarrhoea, while rare hepatic injury has been noted with prolonged use.
The market for Trimethadione is driven by the rising global prevalence of epilepsy. This increased diagnosis through early screening and healthcare infrastructure expansion in developing countries contributes to its market growth.
The awareness of refractory absence seizures and insurance coverage, improving access, boosts the market. The industrial Trimethadione procurement is influenced by strict regulations that delay approvals, and high pricing and reimbursement barriers in developing regions. Other factors, like safety concerns over toxicity, supply chain issues with few GMP API suppliers, and competition from modern anticonvulsants like ethosuximide or lamotrigine, affect its sourcing strategies.
Raw Material for Trimethobenzamide Production
According to the Trimethobenzamide production plant project report, the key raw materials used in the production of Trimethobenzamide include p-Hydroxybenzaldehyde, 2-Dimethylaminoethyl Chloride, and Hydroxylamine Hydrochloride.
Production Process of Trimethobenzamide
The extensive Trimethobenzamide production cost report consists of the following major industrial production process:
- From p-Hydroxybenzaldehyde: The production process of Trimethobenzamide involves a one-pot synthesis. First, p-hydroxybenzaldehyde reacts with 2-dimethylaminoethyl chloride and hydroxylamine hydrochloride (with zinc dust), which leads to the formation of intermediate 4-(2-dimethylaminoethoxy)benzylamine. This is followed by acylation with 3,4,5-trimethoxybenzoic acid in the presence of boric acid and polyethene glycol (PEG) that forms Trimethobenzamide as the final product.
Trimethobenzamide has the molecular formula of C21H28N2O5 and a molecular weight of 388.46 g/mol. It is a white to off-white crystalline solid with a melting point of 188.7 degree Celsius for the freebase and 187.5–190 degree Celsius for the hydrochloride salt. It shows low water solubility with a moderate lipophilicity, with a LogP value of 2.29. It is made up of a 3,4,5-trimethoxybenzoyl group linked to a para-alkoxybenzylamine side chain bearing a terminal dimethylamino moiety. It has 10 rotatable bonds and a polar surface area of 69.26 U. It is classified as a tertiary benzamide amine with a pKa of 8.78. It shows solubility in organic solvents like DMSO and methanol, but limited aqueous solubility. It shows oral bioavailability of approximately 10-20% in humans due to limited absorption and first-pass hepatic metabolism, and undergoes hepatic biotransformation via hydroxylation and conjugation.
